Sign in

Private company

BURZYNSKI RESEARCH INSTITUTE INC

BURZYNSKI RESEARCH INSTITUTE INC is an American in vitro and in vivo diagnostic substances company.1 It is headquartered in Houston, Texas.1

Last updated Oct 21, 2026.

Overview

$0Revenue, fiscal 20252
-$1.4MNet income, fiscal 20252
  • IndustryIn Vitro & In Vivo Diagnostic Substances1
  • HeadquartersHouston, Texas1
  • Incorporated inDE3
  • Business address12000 Richmond Ave, Houston, Tx 770823
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Burzynski Research Institute, Inc. (the “Company”) was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name “Antineoplastons.” The Company believes Antineoplastons are useful in the treatment of human cancer and is currently reviewing data of its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons have not been approved for sale or use by the Food and Drug Administration of the United States Department of Health and Human Services (“FDA”) or anywhere in the world. In the event Antineoplastons receive such approval and are registered in the United States or Canada, of which there can be no assuranc…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue56789102$0 in 2025
02018: $0$020182019: $0$020192020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $0$020242025: $0$02025
Operating income56789102-$1.4M in 2025−14% since 2018
-$2.0M-$1.5M-$1.0M-$500.0K02018: -$1.6M-$1.6M20182019: -$1.6M-$1.6M2019+2%2020: -$1.6M-$1.6M2020−0%2021: -$1.3M-$1.3M2021−20%2022: -$976.7K-$976.7K2022−25%2023: -$916.3K-$916.3K2023−6%2024: -$1.3M-$1.3M2024+46%2025: -$1.4M-$1.4M2025+4%
Net income102-$1.4M in 2025+51% since 2023
-$1.5M-$1.0M-$500.0K02023: -$916.3K-$916.3K20232024: -$1.3M-$1.3M2024+46%2025: -$1.4M-$1.4M2025+4%
Fiscal year20182019202020212022202320242025
Revenue$05$06$07$08$09$010$02$02
Research and development$1.3M5$1.1M6$1.2M7$1.0M8$759.5K9$718.5K10$865.0K2$1.0M2
Operating expenses$976.7K9$916.3K10$1.3M2$1.4M2
Operating income-$1.6M5-$1.6M6-$1.6M7-$1.3M8-$976.7K9-$916.3K10-$1.3M2-$1.4M2
Income before tax-$976.7K9-$916.3K10-$1.3M2-$1.4M2
Income tax$07$08$09$010$02$02
Net income-$916.3K10-$1.3M2-$1.4M2
Earnings per share-$0.018-$0.019-$0.0110-$0.012-$0.012
Earnings per share (diluted)-$0.018-$0.019-$0.0110-$0.012-$0.012
Shares (weighted, basic)131.4M shares9131.4M shares10131.4M shares2131.4M shares2
Shares (weighted, diluted)131.4M shares9131.4M shares10131.4M shares2131.4M shares2

Compare BURZYNSKI RESEARCH INSTITUTE INC with another company

What it owns

What BURZYNSKI RESEARCH INSTITUTE INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8472 Feb 28, 2025$1.3K2 Feb 29, 2024−35.3%

Properties, in its own words

The Company does not own or invest in real estate, interests in real estate, real estate mortgages or securities of or interests in persons primarily engaged in real estate activities.

The Company conducts its business in premises owned by Dr. Burzynski. Pursuant to arrangements with Dr. Burzynski (see “Certain Relationships and Related Transactions, and Director Independence—Research Funding Arrangements”), the Company occupies (i) 675 square feet at 12707 Trinity Drive, Stafford, Texas for office, laboratory and medical research purposes and (ii) 540 square feet at 9432 Katy Freeway, Houston, Texas for its executive offices. Management of the Company believes that each of these properties is adequately covered by insurance.

Item 2 of the 10-K filed May 20, 2025.4

Leadership

Who has led BURZYNSKI RESEARCH INSTITUTE INC, and when. Pick a name to see everywhere that person has worked.

President

  1. Stanislaw Burzynski2012
201520202025
Board members and other officers (8)

Timeline

  1. May 12, 20268-K Other events22
  2. Apr 23, 20268-K Executive or director change23
  3. Sep 11, 20258-K Change of auditor24
  4. Jul 24, 20258-K Change of auditor25
  5. May 22, 20238-K Entered a material agreement26
  6. Apr 6, 20238-K Executive or director change27
  7. Oct 6, 20218-K Executive or director change28

Filings

26 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 7 major events, 1 insider forms. The latest 20:

  1. May 12, 20268-K EDGAR
  2. Apr 23, 20268-K EDGAR
  3. Jan 13, 202610-Q EDGAR
  4. Oct 14, 202510-Q EDGAR
  5. Sep 11, 20258-K/A EDGAR
  6. Jul 24, 20258-K EDGAR
  7. Jul 15, 202510-Q EDGAR
  8. May 20, 202510-K EDGAR
  9. Jan 13, 202510-Q EDGAR
  10. Oct 10, 202410-Q EDGAR
  11. Jul 15, 202410-Q EDGAR
  12. May 29, 202410-K EDGAR
  13. Jan 16, 202410-Q EDGAR
  14. Oct 12, 202310-Q EDGAR
  15. Jul 13, 202310-Q EDGAR
  16. May 25, 202310-K EDGAR
  17. May 22, 20238-K EDGAR
  18. Apr 6, 20238-K EDGAR
  19. Jan 13, 202310-Q EDGAR
  20. Oct 13, 202210-Q EDGAR

The 26 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How BURZYNSKI RESEARCH INSTITUTE INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBURZYNSKI RESEARCH INSTITUTE INC1
  • CIK0000724445
  • Employer ID (EIN)76-01368104
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsFebruary 281
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address12000 Richmond Ave, Houston, TX 770821
  • Mailing address9432 Katy Freeway, Houston, TX 770551
  • Phone(713) 335-56971
  • Shares outstanding131,448,444 as of Jan 13, 202612
  • Public float$1.0M as of Aug 30, 20244
  • AuditorPannell Kerr Forster, Houston, Texas PCAOB ID 342; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceNov 25, 19971
  • Filings147 in all: 10-Q (53), 10QSB (25), 10-K (17), 8-K (17), 10KSB (8), 5 (7), 10SB12G/A (4), 3 (3)1
    All 17 form types

    CORRESP (3), UPLOAD (3), 10-K/A (1), 10KSB/A (1), 10KSB40 (1), 10SB12G (1), 4 (1), 8-K/A (1), NT 10-K (1)

  • Latest filingsAnnual report (10-K) May 20, 2025
    Quarterly report (10-Q) Jan 13, 2026
    Latest 8-K (8-K) May 12, 2026

Securities registered for trading

ClassSymbolExchange
BZYR

From the cover page of the 10-K filed May 20, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks BURZYNSKI RESEARCH INSTITUTE INC names in Item 1A of its 10-K filed May 20, 2025: 25 risks under these headings, as written.4

  • Risks Relating to Our Business and Industry
  • Products that appear promising in research and development may be delayed or may fail to reach later stages of clinical development.
  • There is no assurance that Antineoplaston will be safe, effective or receive regulatory approval.
  • Our source of funding is limited. If we fail to obtain additional financing when needed, we may be unable to complete the development, regulatory approval and commercialization of Antineoplaston.
  • We have a history of net losses, we anticipate additional losses and we may not become profitable.
  • The failure to enroll patients for clinical trials may cause delays in developing our product candidates.
  • There is no assurance that we will be granted regulatory approval for Antineoplaston.
  • Clinical trials are expensive and time consuming, and any failure or delay in commencing or completing clinical trials for our product candidates could severely harm our business.
  • We depend on the Burzynski Clinic (and, possibly, in the future, other third-parties) to conduct and manage our clinical trials. If the Burzynski Clinic and these other third-parties do not successfully carry out their contractual duties or meet expected timelines, we may face costs and delays that may prevent or delay us from obtaining regulatory approval for or commercializing our product candidates, which could substantially harm our business.
  • Antineoplaston may never achieve market acceptance even if we obtain regulatory approval.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than we do.
  • If we are unable to enter into agreements with partners to perform sales and marketing functions, or build these functions ourselves, we will not be able to commercialize our product candidates.
The other 14 risks
  • We depend on key individuals to maintain and manage our business in a rapidly changing market.
  • We may face risks related to securities litigation that could result in significant legal expenses and settlement or damage awards.
  • Risks Related to Regulatory Matters
  • Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization.
  • Even if regulatory approval is received for our product candidates, the later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions, including withdrawal of the product from the market.
  • If we fail to establish and maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our consolidated operating results, our ability to operate our business, and our stock price, and could result in litigation or similar actions.
  • Risks Related to Intellectual Property Matters
  • If we are unable to maintain and enforce our proprietary rights, we may not be able to compete effectively or operate profitably.
  • If we are unable to obtain intellectual property rights to develop or market our products or we infringe on a third-party patent or other intellectual property rights, we may need to alter or terminate a product development program.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights in, or to use, our technology.
  • Risks Related to the Ownership of Our Common Stock
  • An active, liquid trading market for our common stock may not develop.
  • Our principal shareholders, executive officers and directors own a significant percentage of our common stock and will continue to have significant control of our management and affairs, and they can take actions that may be against your best interests.
  • Investors may face significant restrictions on the resale of our common stock due to federal regulations of penny stocks.
  • The trading price of our common stock may be volatile.
  • We may seek to raise additional capital in the future; however, such capital may not be available to us on reasonable terms, if at all, when or as we require additional funding. If we issue additional shares of our common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing stockholders would experience further dilution.
  • Because we do not expect to pay dividends on our common stock, stockholders will benefit from an investment in our common stock only if it appreciates in value.

Legal proceedings

The Company’s activities are subject to regulation by various governmental agencies, including the FDA, which regularly monitor the Company’s operations and often impose requirements on the conduct of its clinical trials and other aspects of the Company’s business operations. The Company’s policy is to comply with all such regulatory requirements. From time to time, the Company is also subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The Company seeks to minimize its exposure to claims of this type wherever possible.

Currently, the Company is not a party to any material pending legal proceedings. Moreover, the Company is not aware of any such legal proceedings that are contemplated by governmental authorities with respect to the Company.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28